The Global Recombinant DNA Technology Market will grow considerably in the coming years due to exceptional scientific advancements in gene therapy. According to a report by Fortune Business Insights, titled “Recombinant DNA Technology Market Size, Share and Global Trend By Product (Vaccines, Therapeutic Agents, Recombinant Protein, Others), By Component (Vectors, Expression System, Others), By Application (Diagnostics, Therapeutics, Food and Agriculture, Others), By End User (Biotechnology and Pharmaceutical Companies, Diagnostic Laboratories, Academic and Government Research Institutes, Other) and Geography Forecast till 2026,” the market will derive growth from the growing emphasis on research and development of recombinant DNA.
Browse Complete Report Details @
The recombinant DNA technology involves the process of combining molecules of two different species that are used to produce a new genetic combination. The applications of recombinant DNA technology across diversified domains have led to an increased global adoption across the world.
Some of the Main Key Players Covered in the Report
- Novartis AG
- Thermo Fisher Scientific Inc.
- Sanofi Pasteur Limited
- Merck KGaA, Genentech Inc.
- GlaxoSmithKline plc.
- Eli Lilly and Company
- Pfizer Inc.
- Janssen Pharmaceuticals Inc.
North America to Emerge as Leading Region; Strategic Collaborations are Key Growth Drivers
The report provides segmentation of the global recombinant NA technology market based on several aspects such as product, component type, application, end users, and regional demographics. Based on regional demographics, the report highlights some of the leading regions that have made their name heard in the global recombinant DNA technology market in recent years. Among all regions, Fortune Business Insights expects North America to emerge dominant in the coming years.
Growing investment in research and development of recombinant DNA technology, combined with increasing number of company collaborations will aid the growth of the recombinant DNA technology market in the coming years.
Besides healthcare, recombinant DNA finds applications in agriculture and farming. The recombinant DNA technology is being developed to produce genetically modified crops. The report highlights a few of the applications of the recombinant DNA technology and gauges the impact of these technologies on the global market.
Get Sample PDF Brochure @
Backed by Successful Clinical Trials, Recombinant DNA Will Derive Several Usage Approvals
The exceptional properties possessed by recombinant DNA technology have led to a huge demand across the world. The growing demand for recombinant DNA technology is matched by the huge emphasis on the research and development of newer technologies. Growing emphasis on research and development has yielded several successful clinical trials, which in turn has brought about numerous usage approvals from regulatory authorities.
In August 2017, the United States Food and Drug Administration announced that it has passed approval for the ‘Kymriah’, a recombinant DNA technology aimed at the treatment of acute lymphoblastic leukemia in young as well as adult patients. The FDA went on to state that this would bee the first ever gene therapy treatment method which was approved in the United States.
Fortune Business Insights has predicted this was a major breakthrough in the recombinant DNA industry and states that this will be a step forward for the global recombinant DNA market. The report includes several usage approvals and gauges the impact of major activities on the growth of the global recombinant DNA technology market.
More Trending Topics from Fortune Business Insights: